Structure Therapeutics' oral weight-loss drug, GSBR-1290, demonstrated 6% body weight loss in 12 weeks with improved side effects in mid-stage trials.

Structure Therapeutics' oral weight-loss drug, GSBR-1290, showed promising early data in mid-stage trials, with patients losing over 6% of their body weight in 12 weeks. The drug's side effects improved over time without signs of liver toxicity. Structure Therapeutics' stock increased by over 78% after the announcement, and the weight-loss market is predicted to reach $130 billion by 2030.